These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 10816681)

  • 61. A case report of naltrexone for alcoholism in a liver transplant recipient: side effects and safety.
    Weinrieb RM; O'Brien CP
    Am J Addict; 2004; 13(5):495-7. PubMed ID: 15764427
    [No Abstract]   [Full Text] [Related]  

  • 62. A pilot study to assess the impact of naltrexone implant on accidental opiate overdose in 'high-risk' adolescent heroin users.
    Hulse GK; Tait RJ
    Addict Biol; 2003 Sep; 8(3):337-42. PubMed ID: 13129836
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A double-blind, placebo-controlled study of the opiate antagonist, naltrexone, in the treatment of kleptomania.
    Grant JE; Kim SW; Odlaug BL
    Biol Psychiatry; 2009 Apr; 65(7):600-6. PubMed ID: 19217077
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Detoxication in opiate addiction and prevention of recurrence: administration of naltrexone and cognitive behavior therapy].
    Roozen HG; Deden AL; Kerkhof AJ; Vorsteveld JP; van den Brink W
    Ned Tijdschr Geneeskd; 1997 Dec; 141(49):2377-80. PubMed ID: 9554156
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Effect of oral naltrexone on pruritus in cholestatic patients.
    Mansour-Ghanaei F; Taheri A; Froutan H; Ghofrani H; Nasiri-Toosi M; Bagherzadeh AH; Farahvash MJ; Mirmomen S; Ebrahimi-Dariani N; Farhangi E; Pourrasouli Z
    World J Gastroenterol; 2006 Feb; 12(7):1125-8. PubMed ID: 16534857
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Risks associated with the inappropriate use of naltrexone in the treatment of opioid dependence.
    Latt NC
    Med J Aust; 1999 Nov; 171(9):500-1. PubMed ID: 10615348
    [No Abstract]   [Full Text] [Related]  

  • 67. High-performance liquid chromatographic determination of naltrexone in plasma of hemodialysis patients.
    Kambia K; Bah S; Dine T; Azar R; Odou P; Gressier B; Luyckx M; Brunet C; Ballester L; Cazin M; Cazin JC
    Biomed Chromatogr; 2000 May; 14(3):151-5. PubMed ID: 10850617
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Rationale for treating pruritus complicating chronic liver disease with opiate antagonists.
    Jones EA
    Curr Gastroenterol Rep; 2004 Apr; 6(2):87-8. PubMed ID: 15191684
    [No Abstract]   [Full Text] [Related]  

  • 69. Review of naltrexone, a long-acting opiate antagonist.
    Crabtree BL
    Clin Pharm; 1984; 3(3):273-80. PubMed ID: 6329589
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Naloxone for intractable pruritus?
    Zuckerman E; Schar M; Korula J
    Am J Gastroenterol; 1997 Jan; 92(1):183-4. PubMed ID: 8995978
    [No Abstract]   [Full Text] [Related]  

  • 71. The use of opiate antagonists for recurrent self-injurious behavior.
    Buzan RD; Thomas M; Dubovsky SL; Treadway J
    J Neuropsychiatry Clin Neurosci; 1995; 7(4):437-44. PubMed ID: 8555746
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Outcome and six month follow up of patients after Ultra Rapid Opiate Detoxification (UROD).
    Albanese AP; Gevirtz C; Oppenheim B; Field JM; Abels I; Eustace JC
    J Addict Dis; 2000; 19(2):11-28. PubMed ID: 10809517
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Use of oral naltrexone for severe pruritus due to cholestatic liver disease in children.
    Zellos A; Roy A; Schwarz KB
    J Pediatr Gastroenterol Nutr; 2010 Dec; 51(6):787-9. PubMed ID: 20948447
    [No Abstract]   [Full Text] [Related]  

  • 74. Monitored naltrexone without counseling for alcohol abuse/dependence in schizophrenia-spectrum disorders.
    Batki SL; Dimmock JA; Wade M; Gately PW; Cornell M; Maisto SA; Carey KB; Ploutz-Snyder R
    Am J Addict; 2007; 16(4):253-9. PubMed ID: 17661192
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Use of naltrexone in postmenopausal women with exaggerated insulin secretion: a pilot study.
    Cucinelli F; Soranna L; Perri C; Barini A; Cento RM; Mancuso S; Lanzone A
    Fertil Steril; 2004 Apr; 81(4):1047-54. PubMed ID: 15066462
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Response to Degenhardt et al.: 'depot naltrexone use for opioid dependence in Australia: large-scale use of an unregistered medication in the absence of data on safety and efficacy'.
    Brewer C
    Drug Alcohol Rev; 2008 Jul; 27(4):447-8; author reply 448-9. PubMed ID: 18584398
    [No Abstract]   [Full Text] [Related]  

  • 77. A morphine/naltrexone combination (Embeda) for pain.
    Med Lett Drugs Ther; 2010 Mar; 52(1334):22-3. PubMed ID: 20336033
    [No Abstract]   [Full Text] [Related]  

  • 78. Opioid receptor antagonists in the treatment of pathological gambling.
    Coppola M; Mondola R
    J Opioid Manag; 2017; 13(4):205-206. PubMed ID: 28983886
    [No Abstract]   [Full Text] [Related]  

  • 79. Naltrexone: report of lack of hepatotoxicity in acute viral hepatitis, with a review of the literature.
    Brewer C; Wong VS
    Addict Biol; 2004 Mar; 9(1):81-7. PubMed ID: 15203443
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Intraoperative high-dose remifentanil in a patient on naltrexone therapy.
    Schwab CA; Wright DA
    Anaesth Intensive Care; 2000 Dec; 28(6):701-3. PubMed ID: 11153302
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.